Year: 2026

LOUISVILLE, Ky., June 09, 2026 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage, media and AdTech solutions, today announced that it will be added to the Russell 3000® Index effective when the US market opens on June 29, 2026, as part of the Russell indexes reconstitution. The June reconstitution captures up to the 4,000 largest US stocks as of April 30, ranked by total market capitalization. Membership in the Russell 3000® Index, which remains in place for half a year, also means automatic inclusion in the small-cap Russell 2000® Index as well as the appropriate growth and value-style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization...

MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Jared Oasheim, the Company’s Chief Financial Officer, will be stepping down from his role to pursue other professional opportunities. To support a seamless transition, Mr. Oasheim will remain with the Company until a successor is appointed and remain available as an advisor through February 2027. “Jared has been an integral part of CVRx since 2015, and has made a lasting mark on our company over the past decade” said Kevin Hykes, President and Chief Executive Officer of CVRx. “He led CVRx through its initial public offering and built the disciplined finance...

WASHINGTON, June 09, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of former healthcare executive Sean O’Reilly as a Senior Managing Director in the firm’s Healthcare Risk Management & Advisory practice. Mr. O’Reilly brings more than 25 years of experience advising healthcare organizations on compliance program design, regulatory risk management and operational integrity across a range of healthcare sectors, including Medicare Advantage, Medicaid, employer group medical and specialty insurance, military healthcare, hospice, home health, value-based primary care and pharmacy. In his role at FTI Consulting, Mr. O’Reilly will advise clients on the design, implementation and improvement of enterprise compliance programs, focusing on risk identification, control development and regulatory...

Competitive eating icon brings championship mindset to everyday wellness routines OMAHA, NE, June 09, 2026 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (Nasdaq: FTLF), a leader in innovative nutritional supplements and wellness products, today announced a new partnership between Dr. Tobias® and legendary competitive eater Joey Chestnut.  The campaign, built around the tagline “Cleanse Like a Winner,” brings together Chestnut’s championship mindset with Dr. Tobias’ focus on everyday wellness and digestive health support. The collaboration pairs one of the most recognizable names in sports entertainment with Dr. Tobias Colon 14 Day Cleanse in a campaign designed to inspire people to reset routines, stay consistent, and approach wellness with the mindset of a champion. Known worldwide for his record-breaking performances and larger-than-life...

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed Phase 2 trial utilizes novel sequential treatment approach designed to combine rapid symptom control of FcRn inhibition with sustained disease modification of B-cell depletion therapy NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) (the “Company” or “TG Therapeutics”), today announced positive topline Phase 1 data for BRIUMVI in patients with myasthenia gravis (MG) and the initiation of a Phase 2 clinical trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated,...

$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13.5 million financing for Angel Pharmaceuticals Ltd. (Angel Pharma), the Company’s collaboration partner in China. Corvus co-founded Angel Pharma in 2020 to enable the clinical development and commercialization of its pipeline in China as well as the development of other novel drugs. Corvus is Angel Pharma’s largest shareholder and is investing $5 million in the current financing. The funding is anticipated...

Sprouts Listing Gives GURU Nationwide Access to the U.S. Natural Channel’s Most Engaged, Health-Conscious Shopper MONTRÉAL, June 09, 2026 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company“), Canada’s leading organic energy drink brand1, today announced the nationwide availability of GURU Lite and its four Zero Sugar flavors at Sprouts Farmers Market locations across the United States, effective June 22, 2026.GURU’s energy drink lineup offers a unique combination that the category rarely delivers at scale: organic ingredients, zero sugar, no sucralose, and no aspartame; a clean-label standard that speaks directly to the Sprouts shopper. The listing marks a significant milestone in GURU’s U.S. growth strategy, bringing its clean-label, organic lineup...

Monthly CPP Reaches Record Level TORONTO, June 09, 2026 (GLOBE NEWSWIRE) — (TSX: CGX) – Cineplex, Canada’s leading entertainment and media company, reported box office revenues of $60.5 million for May 2026, delivering its highest May box office since 2019.Period 2025 Box Office (i) 2026 Box Office (i) 2026 as a Percentage of 2025April $51,375 $60,012 117%May $55,331 $60,450 109%Q2 to date $106,706 $120,462 113%(i) Amounts are in thousands of dollars. Cineplex’s May performance was driven by a compelling and diverse film slate, resulting in strong audience engagement, with notable strength among younger moviegoers. Top performing films reflected a balance of franchise and original content, and included The Devil Wears Prada 2, Michael (continuing from April), Obsession, Star Wars: The Mandalorian and Grogu, and...

Nes Ziona, June 09, 2026 (GLOBE NEWSWIRE) — QTREX Quantum Ltd. (Nasdaq: QTEX) (“QTREX” or the “Company”), a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that the Israel Innovation Authority (“IIA”) has awarded the Company an approximately $1 million grant to support the development of a purpose-built dielectric material engineered for high-density, low-loss RF signal routing in scalable superconducting quantum computing systems. QTREX’s program targets one of the core scaling constraints in superconducting quantum computing: the growing need to move more RF and microwave signals through cryogenic environments with lower loss, higher density and fewer assembly points. QTREX is developing the material as a native layer within...

Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that company management will participate in 1-on-1 investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, in Miami, FL. Mr. Daniel Tassé, CEO, will not be available for the previously scheduled fireside chat due to an unavoidable disruption of planned travel to the conference. About DBV TechnologiesDBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently...